XEJ Forecast — Price Target — Prediction for 2027
This article provides an overview of Accuray Incorporated (XEJ) stock, traded on the Hannover Stock Exchange. It covers financial metrics like earnings per share, revenue, net income, and EBITDA, along with future earnings and revenue estimates. The company does not pay dividends and has 809 employees as of October 6, 2026.
Accuray, Samsung NeuroLogica Partner to Advance Volumetric Imaging for CyberKnife
Accuray and Samsung NeuroLogica have announced a collaboration to enhance volumetric imaging capabilities for the CyberKnife System, combining Samsung's mobile CT expertise with Accuray's robotic radiosurgery and motion management. This partnership aims to improve treatment-room imaging, support future adaptive radiotherapy workflows, and provide more informed decision-making for clinicians, particularly for thoracic, abdominal, and pelvic malignancies. The collaboration was announced at the American Society of Radiation Oncology (ASTRO) Annual Meeting and reflects Accuray's strategy to address customer priorities through targeted partnerships.
Japan Approves Accuray’s Cyberknife M6 System for Radiation Therapy Patients
Accuray Inc. has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare for its Cyberknife M6 system, marking the third version of this robotic radiosurgery system to be approved in Japan. The Cyberknife M6 offers high-precision radiation therapy for cancer patients, aiming to reduce side effects and preserve quality of life by minimizing radiation exposure to healthy tissue. This approval is a significant milestone in Accuray's strategic growth plan for the Japanese market, providing advanced treatment options to clinicians and patients.
Accuray Incorporated Stock Analysis: Bearish Trends and Key Levels Near Term
Accuray Incorporated (ARAY) stock is experiencing a strong bearish trend, trading at $0.22, significantly below its major moving averages, including the EMA200 at $0.50. Despite some short-term oversold indicators, the overall sentiment remains negative, with key resistance at $0.23 and support at $0.21. A sustained move above $0.24 would be needed for a constructive shift, otherwise, the downtrend is expected to continue.
Why Is Accuray Stock Gaining Monday?
Accuray stock surged after announcing a collaboration with Samsung NeuroLogica to enhance volumetric imaging for its CyberKnife system. This partnership aims to improve treatment visualization and support adaptive radiation therapy workflows. The company also recently expanded its collaboration with RaySearch Laboratories and reported a Q4 loss that beat Street estimates, despite a revenue miss.
Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
Accuray and Samsung NeuroLogica have announced an advanced volumetric imaging collaboration for the CyberKnife® System, aiming to enhance treatment efficiency and decision-making in radiation oncology. This partnership combines Samsung NeuroLogica's expertise in mobile CT and volumetric imaging with Accuray's precision treatment delivery. The collaboration is expected to provide clinicians with better visualization of patient anatomy at the time of treatment, potentially improving outcomes for patients with various cancers.
Accuray Incorporated (ARAY) Partners With Samsung NeuroLogica on Volumetric Imaging for CyberKnife
Accuray Incorporated (ARAY) has announced a partnership with Samsung NeuroLogica to develop advanced volumetric imaging capabilities for its CyberKnife System. This collaboration is an early-stage strategic move to enhance the CyberKnife, with development proceeding in phases and no commercial product announced yet. While the timeline and revenue impact are uncertain, early clinician involvement may de-risk future adoption.
Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
Accuray Incorporated announced a collaboration with Samsung NeuroLogica to enhance volumetric imaging capabilities for the CyberKnife® System. This partnership aims to integrate Samsung's expertise in mobile CT and volumetric imaging with Accuray's precision treatment delivery, addressing customer priorities for improved treatment efficiency and informed decision-making in radiation oncology. The companies are exploring how this technology can provide better visualization of patient anatomy during treatment and support adaptive clinical workflows, with The Royal Marsden NHS Foundation Trust being the first center to participate in exploring these advancements.
A new collaboration will explore whether 3D scans can inform radiation treatment
Accuray and Samsung NeuroLogica are collaborating to integrate volumetric imaging into the Accuray CyberKnife® System, aiming to enhance radiation treatment decisions by providing more detailed patient anatomy information. The Royal Marsden is the first center globally to participate in this phased development, which seeks to explore future workflows that adapt treatment to a patient's anatomy. This partnership leverages Samsung NeuroLogica's expertise in mobile CT and volumetric imaging with Accuray's precision treatment delivery capabilities.
Accuray, RaySearch to Collaborate on Online Adaptive Radiation Therapy
Accuray Inc. and RaySearch Laboratories have announced an expanded collaboration to accelerate the adoption of online adaptive radiation therapy. This partnership combines Accuray's radiation therapy platforms and imaging with RaySearch's treatment planning software, initially focusing on Accuray's Radixact system and later extending to CyberKnife. The goal is to provide more personalized and efficient radiation treatments by allowing real-time adjustments based on patient anatomy.
Accuray Incorporated (ARAY) options chain
This page provides the options chain for Accuray Incorporated (ARAY), showing delayed options data. It indicates that there are currently no calls or puts available for the specified expiration date of June 18, 2026. The stock's current trading price is also displayed.
ACCURAY INC SEC Filing (Sep 14, 2026)
This article reports on an SEC filing (Form EFFECT) by Accuray Inc. (ARAY) on September 14, 2026, which was accepted by the SEC on the same day. The filing indicates a Notice of Effectiveness for an S-3 form, with an effectiveness date of September 11, 2026, at 4:00 P.M. The article also provides recent news and other SEC filings related to Accuray.
Accuray and RaySearch agree to collaboration integrating RayStation software with Accuray platforms to accelerate Accuray’s online adaptive capabilities
Accuray Incorporated and RaySearch Laboratories AB have announced an expanded collaboration to accelerate Accuray's adoption of online adaptive radiation therapy. The agreement involves Accuray purchasing $8 million worth of RayStation licenses, with revenue recognized primarily in Q3 and Q4 2026. This partnership aims to integrate RaySearch's treatment planning software with Accuray's radiation therapy platforms to enable more personalized and efficient cancer treatments, initially focusing on the Radixact system and later extending to CyberKnife.
Accuray Inc. (NASDAQ: ARAY) Announces Resale of 6.83M Shares Linked to Warrants Priced at $1.50, $1.25, and $0.01
Accuray Inc. (NASDAQ: ARAY) has announced the resale of up to 6.83 million common shares by selling stockholders, tied to warrants exercisable at $1.50, $1.25, and $0.01 per share. The company will not receive proceeds from these resales, but any cash warrant exercises would be used for general corporate purposes. This transaction involves various warrant types, including Super Premium, Premium, and Penny Warrants, issued as part of a financing agreement from June 2025.
What Accuray’s (ARAY) $8 Million RaySearch Deal Means for Its Adaptive Therapy Push
Accuray Inc. (ARAY) has entered an $8 million agreement with RaySearch Laboratories to extend their alliance, aiming to accelerate the adoption of online adaptive radiation therapy. This collaboration integrates Accuray's imaging and radiation therapy platforms with RaySearch's planning solutions, focusing initially on the Radixact system. While the deal supports Accuray's transformation plan and growth strategy, potential risks include slow adoption by healthcare providers and dependency on RaySearch's execution.
Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities
Accuray and RaySearch Laboratories have announced a collaboration to integrate RaySearch's RayStation software with Accuray's radiation therapy platforms. This partnership aims to accelerate Accuray's online adaptive radiation therapy capabilities, initially focusing on the Radixact system and later extending to CyberKnife. Accuray will purchase $8 million worth of RayStation licenses, and the companies will jointly market and support the solutions, enhancing personalized and efficient cancer treatments.
Accuray (NASDAQ: ARAY) clears 6.8M shares for investors to resell
Accuray has filed an S-3/A amendment to register approximately 6.83 million common stock shares for resale by certain lending stockholders. These shares are linked to warrants issued in connection with a $18.25 million delayed draw term loan and other financing arrangements. Accuray will not receive proceeds from the resales but may receive cash if the warrants are exercised, which it plans to use for general corporate purposes.
Accuray Inc (ARAY) (Q4 2026) Earnings Call Highlights: Strategic Transformation and Financial ...
Accuray Inc. reported its Q4 and full fiscal year 2026 earnings, highlighting a strategic transformation that exceeded cost-saving targets and strengthened its financial position through a transaction with TCW. Despite a decline in overall revenue, particularly in product sales due to geopolitical tensions in China, service revenue saw growth. The company is focusing on "Transformation Phase 2," emphasizing innovation, cost reduction, market expansion, and service revenue growth, while refraining from providing formal fiscal 2027 guidance due to market uncertainties.
Accuray Inc (NASDAQ: ARAY) Discloses 18.7% Beneficial Ownership by TCW Including Warrants
Accuray Inc. (NASDAQ: ARAY) has disclosed that The TCW Group holds an 18.7% beneficial ownership, which includes 27,527,916 common shares convertible from warrants. This ownership stems from an amended financing agreement that provides a covenant holiday until December 31, 2027, grants TCW preferred director rights, and includes a $15 million fee if stockholder approval is not secured.
[SCHEDULE 13D/A] ACCURAY INC Amended Major Shareholder Report
This SEC filing (SCHEDULE 13D/A) for ACCURAY INC (ARAY) details an amended major shareholder report by The TCW Group, Inc. It describes a financing agreement where Accuray received $15.0 million and issued penny warrants, with a planned total of $55.0 million in preferred financing remaining unclosed. The filing highlights TCW's significant beneficial ownership (18.7%) through warrants and its governance rights, including the ability to designate directors, contingent upon the closing of the preferred stock issuance.
Balance Sheet Rescue Meets China Drag in Accuray’s (ARAY) Mixed Quarter
Accuray (ARAY) experienced a mixed fiscal fourth quarter and full year 2026, with a significant financial rescue from TCW Asset Management improving its balance sheet and liquidity. Despite this, the company's product revenue declined sharply due to geopolitical and trade policy issues in China, leading to a full-year operating loss and a decision not to issue future guidance. While service revenue and cost savings are positive, the ongoing China drag creates uncertainty for the company's growth prospects.
Accuray (ARAY) sends definitive proxy to shareholders
Accuray Inc. has submitted a definitive proxy statement to the SEC, detailing proposals for its 2026 Special Meeting of Stockholders on October 6, 2026. The company is seeking stockholder approval for a financing transaction involving the issuance of Series A Convertible Preferred Stock and warrants, a significant increase in authorized common stock, and a reverse stock split. These actions are crucial for strengthening Accuray's financial position, addressing liquidity concerns, and maintaining its listing on The Nasdaq Capital Market.
Penny-priced Accuray (NASDAQ: ARAY) warrants set up lender share resales
Accuray Incorporated has filed an amended Form S-3 registration statement to allow certain existing lenders to resell up to 6,834,308 shares of common stock. These shares are tied to previously issued Super Premium, Premium, and Penny Warrants, which were granted in connection with a senior secured Financing Agreement including an $18.25 million delayed draw term loan. Accuray will not receive proceeds from the resales but would benefit if warrant holders exercise them for cash; the company's stock currently trades at $0.29 per share, while warrant exercise prices range from $0.01 to $1.50.
Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results
Accuray Incorporated reported its financial results for the fourth quarter and fiscal year 2026, highlighting a transformational year with over $20 million in cost and margin improvements, exceeding initial targets. The company secured a comprehensive financing transaction with TCW Asset Management to strengthen liquidity and enhance financial flexibility, while also expanding its strategic partnership ecosystem. Despite a decrease in total net revenue and product revenue, service revenue increased, and Accuray expressed a focus on sustainable revenue growth and margin expansion for fiscal 2027.
Accuray: Fiscal Q4 Earnings Snapshot
This article provides an earnings snapshot for Accuray's fiscal Q4, noting that the content is protected by Privacy. However, the actual financial details of the earnings report are not included in the provided text.
Accuray Incorporated Q4 Operating Expenses US
This article provides an in-depth financial analysis of Accuray Incorporated's Q4 operating expenses in the US, highlighting key figures and trends. It breaks down the components of their expenditures, offering insights into the company's financial health and operational efficiency during the quarter.
Accuray Incorporated 2026 Q4 - Results - Earnings Call Presentation (NASDAQ:ARAY) 2026-08-20
This article announces that Accuray Incorporated has published its Q4 2026 earnings call presentation. The presentation was released in conjunction with their earnings call on August 20, 2026. Seeking Alpha's transcripts team prepared this content.
Aug 19 (Reuters) - Accuray Incorporated Q4 Ne
This article is a Reuters news brief from August 19, reporting on Accuray Incorporated's Q4 results. The content is incomplete, only providing the headline and indicating that it's a financial news update.
Accuray Q4 FY26 slides: transformation gains amid revenue decline
Accuray Incorporated reported a significant 21% year-over-year revenue decline in Q4 FY26, primarily due to falling product sales, although its service revenue grew. Despite a GAAP net loss, the company achieved improved adjusted EBITDA through cost optimization and transformation initiatives, exceeding initial targets. Accuray faces ongoing challenges from geopolitical uncertainties, especially in China, and declined to provide FY27 guidance.
Earnings call transcript: Accuray posts mixed Q4 2026 results as revenue slips
Accuray Inc. reported mixed financial results for Q4 fiscal year 2026, beating EPS estimates but missing revenue forecasts. The company's revenue declined significantly year-over-year, primarily due to a sharp drop in product sales, especially from China, though service revenue saw growth. Accuray did not provide formal guidance for fiscal year 2027 due to geopolitical and tariff uncertainties but outlined expectations for continued service revenue growth and improved margins.
Accuray Reports $100.9 Million Fourth-Quarter Revenue and $1.9 Million Net Loss
Accuray (ARAY) reported fourth-quarter fiscal 2026 revenue of $100.9 million, a 21% decrease year-over-year, and a GAAP net loss of $1.9 million. For the full fiscal year 2026, the company recorded $401.9 million in revenue and a net loss of $49.2 million, declining to provide fiscal 2027 guidance. Insider trading data shows STEVEN F MAYER made three purchases of ARAY stock totaling 250,000 shares for $134,675, while hedge funds showed mixed activity with 59 increasing and 86 decreasing their positions.
Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results
Accuray Incorporated announced its financial results for the fourth quarter and fiscal year ended June 30, 2026. The company reported a 21% decrease in total net revenue for the fourth quarter and a 12% decrease for the full fiscal year, but saw service revenue increase by 6% and 4% respectively. Accuray highlighted its successful transformation plan, exceeding its cost and margin improvement target, and a comprehensive financing transaction that enhanced liquidity.
Accuray: Fiscal Q4 Earnings Snapshot
Accuray Inc. reported a fiscal fourth-quarter loss of $1.9 million, or 2 cents per share, on revenue of $100.9 million. For the full fiscal year, the company's loss widened to $49.2 million, or 40 cents per share, with total revenue reaching $401.9 million. The company's shares were trading at 29 cents, significantly down from $1.51 a year prior.
ARAY Looks 76.5% Undervalued on GF Value™
Accuray Inc (ARAY) is set to release its Q4 earnings on August 19, 2026. Despite a GF Value™ suggesting it is 76.5% undervalued, its low Price-to-Sales ratio and weak GF Score™ (44/100) point to significant financial challenges including persistent losses, negative cash flow, and high bankruptcy risk. However, insider buying and mixed guru activity provide some cautious optimism for potential recovery.
Earnings Preview: Accuray to Report Financial Results Post-market on August 19
Accuray (NASDAQ: ARAY) is scheduled to announce its quarterly earnings post-market on August 19. Analysts are projecting earnings per share of $0.02 and revenue of $111.45 million. The company's stock has seen varied performance recently, including an analyst upgrade from Citigroup and significant insider stock purchases.
Accuray Advances Strategic Priorities Through Key Executive Leadership Appointments
Accuray Incorporated has announced two key leadership appointments to advance its strategic priorities and transformation plan for sustainable, profitable growth. Todd Brown will lead the newly created Enterprise Performance Optimization organization, focusing on improving operational execution, lowering costs, and enhancing supply chain efficiency. Sofiane Laoussadi has been appointed Senior Vice President of Global Services & Solutions to lead the global services organization, aiming to improve customer experience and expand solution-based offerings.
Accuray names two executives to lead transformation efforts
Accuray Incorporated has announced the appointment of Todd Brown as Senior Vice President for a new Enterprise Performance Optimization organization and Sofiane Laoussadi as Senior Vice President, Global Services & Solutions. These appointments are part of the company's "Transformation Phase II" priorities, aimed at enhancing operational execution, optimizing cost structure, and delivering value to customers and shareholders. Brown will focus on working capital, supply chain efficiency, and cost optimization, while Laoussadi will lead global service delivery and customer support.
Accuray (NASDAQ: ARAY) seeks approval for $55M recapitalization, dilution and reverse split
Accuray (NASDAQ: ARAY) is seeking stockholder approval for a significant financing and recapitalization plan, including issuing $55 million in Series A Convertible Preferred Stock and warrants, and a reverse stock split. The plan aims to strengthen liquidity, reduce leverage, and achieve Nasdaq compliance, but will cause substantial dilution for existing shareholders and increase TCW's influence. Stockholders will vote on these proposals at a virtual special meeting on October 6, 2026, with the Board unanimously recommending approval despite the potential for significant dilution and increased influence from TCW.
Accuray Transfers Listing to Nasdaq Capital Market
Accuray (ARAY) has received Nasdaq approval to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective August 6, 2026. This transfer grants the company an additional 180 days, until February 1, 2027, to meet Nasdaq's minimum bid price requirement. Analysts currently rate ARAY as "Hold" with a $0.35 price target, while TipRanks' AI Analyst Spark rates it "Underperform" due to weak financial performance and technical indicators.
Accuray Announced Transfer or Voluntary Withdrawal of Listing
Accuray (ARAY) has received Nasdaq approval to transfer its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective August 6, 2026. The company retains its ARAY symbol and has an additional 180 days, until February 1, 2027, to meet the $1.00 bid price requirement. This information is based on an original SEC Filing.
Radiation therapy company Accuray will discuss results Aug. 19
Accuray (NASDAQ: ARAY) is scheduled to report its fourth quarter fiscal 2026 financial results on August 19, 2026, for the period ending June 30, 2026. Company management will host a conference call that day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. A live webcast and replay of the call will be accessible via the Investor Relations section of Accuray's website.
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
Accuray Incorporated (NASDAQ: ARAY) will report its fourth-quarter fiscal year 2026 financial results on August 19, 2026. The company will host a conference call and webcast for investors at 1:30 p.m. PT/4:30 p.m. ET to discuss the results, which concluded on June 30, 2026. Accuray specializes in radiation therapy solutions for cancer treatment, aiming to improve patient outcomes.
Neuberger Berman Group (ARAY) discloses 5.48M Accuray shares in 13G/A filing
Neuberger Berman Group LLC and its affiliates have disclosed an amended passive investment in Accuray Inc. (ARAY) via a Schedule 13G/A filing. The group beneficially owns 5,484,393 shares, representing 4.6% of Accuray’s common stock, with shared voting and dispositive power. Neuberger Berman Investment Advisers LLC separately holds 5,057,218 shares, or 4.3% of the class.
Accuray | SCHEDULE 13G/A: Others
This article consists solely of the title "Accuray | SCHEDULE 13G/A: Others" and the content "Document". It indicates the filing of a Schedule 13G/A, suggesting an amendment to a previous beneficial ownership report for Accuray. However, no detailed information about the filing or the company is provided.
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
Accuray Incorporated (NASDAQ: ARAY) announced it will report its financial results for the fourth quarter of fiscal year 2026 on August 19, 2026. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss these results, with dial-in and webcast replay options available for investors. Accuray, headquartered in Madison, Wisconsin, specializes in radiation therapy solutions for various cancer treatments.
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
Accuray Incorporated (NASDAQ: ARAY) is scheduled to release its financial results for the fourth quarter of fiscal year 2026 on August 19, 2026. The company will host a conference call and webcast at 1:30 p.m. PT/4:30 p.m. ET to discuss the results, which will cover the period ending June 30, 2026. Details for accessing the call, replay, and live webcast are provided.
Accuray to Report Fourth Quarter Fiscal 2026 Financial Results on August 19, 2026
Accuray Incorporated (ARAY) announced it will report its financial results for the fourth quarter of fiscal year 2026 on August 19, 2026. A conference call hosted by company management will take place at 1:30 p.m. PT/4:30 p.m. ET, with dial-in and webcast details provided for investors and the public. Accuray, headquartered in Madison, Wisconsin, specializes in radiation therapy solutions for oncology and neuro-radiosurgery.
Accuray Number of Employees 2026 | Employee Count & Headcount Data
Accuray, Inc. (ARAY) had 909 employees worldwide as of March 2026, representing an 8.3% decline from 2023. The company is actively hiring, with 40 active job postings in 2026, though this is a 51.9% decline from 2025. The workforce is concentrated in North America, and overall employee sentiment is negative and declining.
Form S-3 Accuray Incorporated For: 31 July By Investing.com
This article from Investing.com announces the filing of Form S-3 by Accuray Incorporated for the period ending July 31. It is a brief administrative notice indicating a regulatory filing has been made by the company. The content primarily consists of navigational elements and market data rather than detailed analysis of the filing itself.
Price to sales forward of Accuray Incorporated – NASDAQ:ARAY
This article provides financial information for Accuray Incorporated (NASDAQ: ARAY), specifically focusing on its price to sales forward metric. It appears to be a data point or a snapshot from a financial platform like TradingView, indicating the value and change of this financial ratio. The core content is a single data point related to ARAY's financial performance.
